

Figure S1. Viability and  $IC_{50}$  values of HepG2, PLC/PRF/5 and Hepa1-6 cell lines treated with (A) OXA and (B) ACT.  $IC_{50}$ , half-maximal inhibitory concentration; ACT, acteoside; OXA, oxaliplatin.




Figure S2. Combination index detection evaluation of OXA and ACT co-administration on HepG2. (A) Dose-effect and (B) CI curve. CI, Combination index; ACT, acteoside; OXA, oxaliplatin; Fa, fraction of system affected by drug.




Figure S3. Combination index detection evaluation of OXA and ACT co-administration on Hepal-6. (A) Dose-effect. (B) CI curve. CI, Combination index; ACT, acteoside; OXA, oxaliplatin; Fa, fraction of system affected by drug.

